Trial Profile
An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2018
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Genentech
- 05 Jun 2018 Results (n=114) of an analysis assessing outcomes in patients with impaired baseline renal function or variant histology, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2017 Interim safety results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 11 Aug 2016 Status changed from recruiting to completed.